Loading clinical trials...
Loading clinical trials...
Effect of Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis. The objective of this research is to determine the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
Shahid Mohammadi hospital
Bandar Abbas, Hormozgan, Iran
Start Date
November 1, 2015
Primary Completion Date
October 1, 2016
Completion Date
November 1, 2016
Last Updated
November 4, 2016
92
ACTUAL participants
IVIG
DRUG
Lead Sponsor
Hormozgan University of Medical Sciences
NCT07421323
NCT05329701
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05730387